Skip to main content
Publish date:

Jim Cramer's Stop Trading! Great Glaxo

The U.K. drug giant might be the best name in the pharma space, he says.

GlaxoSmithKline (GSK) - Get GlaxoSmithKline plc Sponsored ADR Report might be the best of breed when it comes to big-cap pharmaceuticals concerns, and the company is positioning itself to dominate drugstore shelves with its variety of products, Jim Cramer said on CNBC's Stop Trading! segment Monday.

"GlaxoSmithKline is really an amazing company," he said. "This is a share

taker when it comes to aisle space."

The U.K.-based company has the potential to offer the best of everything when it comes to highly diversified drugsellers, he said. Plus, the company isn't afraid to be optimistic when it tells its story or when it comes to giving access to the media.

By contrast, too many companies in the sector, like


(MRK) - Get Merck & Co., Inc. (MRK) Report


Bristol-Myers Squibb

(BMY) - Get Bristol-Myers Squibb Company Report

, spend more time than they should on the defensive. "Bristol is a challenged company every which way but loose," he said.

Cramer also talked telecom, saying he likes


(T) - Get AT&T Inc. Report

better than

TheStreet Recommends


(VZ) - Get Verizon Communications Inc. Report

. He said he believes AT&T could go to $36.

Meanwhile, he said



should have raised its dividend rather than setting plans to buy back stock recently.

At the time of publication, Cramer has no positions in stocks mentioned.

Jim Cramer is a director and co-founder of He contributes daily market commentary for's sites and serves as an adviser to the company's CEO. Outside contributing columnists for and, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Listen to Cramer's RealMoney Radio show on your computer; just click

here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click

here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here. has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from